Download full-text PDF |
Source |
---|
Neurol Neurochir Pol
January 2025
Department of Neuropathology, Institute of Psychiatry and Neurology, Warsaw, Poland.
Front Nutr
January 2025
Nutrition and Food Security Research Center, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
Background And Aim: Although the relationship between selenium and metabolic syndrome (MetS) was previously investigated, the findings were inconsistent. Therefore, we performed a systematic review and dose-response meta-analysis to summarize the association between blood selenium and MetS in adults.
Methods: A comprehensive search was conducted in Medline (PubMed), ISI Web of Science, Scopus, and motor engineering of Google Scholar up to October 1st, 2024.
Cancer Manag Res
January 2025
Department of Gynecologic Oncology, University of California, Irvine-Medical Center, Orange, California, USA.
Endometrial cancer (EC) is the most common gynecologic cancer in developed nations with reported 420,368 new cases worldwide in 2022 and resulting in 97,723 deaths that year; it is also one of the few cancers with expected increases in incidence and mortality, which are expected to increase by 50% and 70%, respectively, by 2045. The mortality from EC can largely be attributed to the advanced stage and recurrent cases. Over the past decade, the standard of care for treatment of primary advanced stage and recurrent EC has been chemotherapy, resulting in a median overall survival (OS) of less than 3 years.
View Article and Find Full Text PDFBiocontrol (Dordr)
November 2024
Department of Entomology and Acarology, Luiz de Queiroz College of Agriculture (ESALQ), University of São Paulo (USP), Piracicaba, SP Brazil.
Unlabelled: A recently discovered koinobiont parasitoid species, Shimbori, 2023, proved to be a promising biological control agent for larvae of (Walker, 1858), (Stoll, 1782), and (J.E. Smith, 1797), all well-known pests that cause critical damage to soybean and corn crops.
View Article and Find Full Text PDFIndian J Endocrinol Metab
December 2024
Department of Endocrinology, Max Super Speciality Hospital, Saket, New Delhi, India.
Introduction: Oral Semaglutide (Sema-o) is the first oral glucagon like peptide-1 receptor analogue (GLP-1RA) commercially available for the treatment of type 2 diabetes (T2D). This study aimed to evaluate the efficacy of Sema-o in patients with T2D when added to the existing therapy.
Methods: This retrospective real-world study enrolled adult patients with diabetes taking Sema-o, with at least one follow-up (from February 2022 till October 2023).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!